tetano
Editor, Senior Moderator
Mult Scler Relat Disord
. 2022 Jan 11;58:103524.
doi: 10.1016/j.msard.2022.103524. Online ahead of print.
Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
Recai Türkoğlu[SUP] 1 [/SUP], Nesrin Baliç[SUP] 1 [/SUP], Tuğçe Kızılay[SUP] 1 [/SUP], Ruziye Erol[SUP] 1 [/SUP], Ece Akbayır[SUP] 2 [/SUP], Vuslat Yılmaz[SUP] 2 [/SUP], Erdem Tüzün[SUP] 3 [/SUP]
Affiliations
Abstract
Background: The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied.
Methods: We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations.
Results: Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices.
Conclusion: Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.
Keywords: COVID-19; CoronaVac; Fingolimod; Multiple sclerosis; SARS-COV-2; Vaccination.
. 2022 Jan 11;58:103524.
doi: 10.1016/j.msard.2022.103524. Online ahead of print.
Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
Recai Türkoğlu[SUP] 1 [/SUP], Nesrin Baliç[SUP] 1 [/SUP], Tuğçe Kızılay[SUP] 1 [/SUP], Ruziye Erol[SUP] 1 [/SUP], Ece Akbayır[SUP] 2 [/SUP], Vuslat Yılmaz[SUP] 2 [/SUP], Erdem Tüzün[SUP] 3 [/SUP]
Affiliations
- PMID: 35033838
- DOI: 10.1016/j.msard.2022.103524
Abstract
Background: The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied.
Methods: We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations.
Results: Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices.
Conclusion: Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.
Keywords: COVID-19; CoronaVac; Fingolimod; Multiple sclerosis; SARS-COV-2; Vaccination.